FDA issues guidance on developing cancer drugs in combination with other treatments
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsNew Drug Application (NDA)PharmaceuticalsProduct developmentRegulatory Intelligence/PolicyRegulatory strategySubmission and registrationUnited StatesUS Food and Drug Administration (FDA)